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The entire early regions of three human isolates of simian virus 40 (SV40), as well as two laboratory strains recovered
from monkeys, were sequenced. The early coding region of each isolate contains a number of nucleotide differences when
compared to the reference strain SV40-776. These differences result in some changes in the predicted amino acid sequence
of the unique region of small t-antigen and in the carboxy (C) terminus of large T-antigen. The amino acid sequence of the
remainder of large T-antigen was absolutely conserved among all isolates. Thus, SV40 large T-antigen contains a variable
domain at the C-terminal end of the molecule. q 1996 Academic Press, Inc.
SV40 is a small DNA virus that has been well-studied Large T-ag is absolutely required for the replication of
for its ability to immortalize and transform rodent and the SV40 genome because it possesses several activi-
human cell lines (1). SV40 encodes two tumor antigens ties needed for initiation of copying of the viral DNA.
in its early region, large T and small t, generated by These include the helicase and ATPase activities, DNA
alternative splicing. The two proteins share 82 amino- binding at the SV40 ori, and recruitment of the cellular
terminal residues in common. Large T-antigen (T-ag) is a DNA polymerase a-primase (24).
complex, multifunctional oncoprotein composed of many The functions of small t-ag have been difficult to delin-
well-defined regions (Fig. 1), whereas relatively less is eate in cultured cells. Small t-ag is not required for trans-
known about small t-antigen (t-ag). Functional studies of formation of most cells (25), although its expression does
these viral proteins in different laboratories have utilized seem to enhance transformation by large T-ag (2, 26–
different isolates of SV40, but there have been no data 28). This helper function may be due to the interaction
to indicate whether all strains of SV40 are identical. We of small t-ag with protein phosphatase 2A (PP2A) or to
report here that there are, in fact, nucleotide differences an effect on p53 stabilization. Small t-ag can bind (29,
in the early region of the genome among SV40 isolates 30) and inhibit (31) PP2A and may be involved in stimulat-
and that the carboxy (C)-terminal sequences of large T- ing cell proliferation by inhibiting PP2A inactivation of
ag represent a variable region. ERKs and MEKs, members of the MAP kinase pathway
Large T-ag can immortalize and transform cells in (32). More recently, it has been suggested that small
the absence of other SV40 genes (2). When the SV40 t-ag may cooperate with large T-ag to induce the stabili-
large T-ag is expressed as a transgene under the con- zation of p53, as cells abortively infected with wild-type
trol of a foreign promoter, it is able to cause tumors in (WT) SV40 failed to exhibit stabilized p53 if small t-ag
a variety of target tissues (3, 4). However, when ex- were not expressed (33). In vivo, expression of small
pressed from its own regulatory region, a large T-ag t-ag concomitant with large T-ag alters the spectrum of
transgene specifically induces choroid plexus papillo- tumors that develop in transgenic mice or in hamsters
mas (5). Large T-ag binds the p53 and pRB tumor sup- injected with SV40 (34, 35), but the precise role played
pressor proteins (6 – 13, reviewed in 14). This binding by small t-ag is not known. Small t-ag is not required for
has been proven to be important for the transforming replication of SV40 in tissue culture (36), but presumably
and tumorigenic abilities of large T-ag (15 – 19) and may plays some role in the natural infection process, as the
play a role in regulating replication of the SV40 genome small t-ag open reading frame has been retained by all
as well (20, 21), although binding of neither protein is viral isolates investigated to date. Small t-ag can trans-
necessary for virus replication in cell culture (22, 23). activate the SV40 early region (37) and some cellular
genes (38–40) and can repress others (41), but the func-
tional relevance of these effects to viral infection is un-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (713) 798-5019. E-mail: jbutel@bcm.tmc.edu. known (42).
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FIG. 1. Functional domains of SV40 large T-ag. The numbers given are the amino acid residues using the numbering system for SV40-776 (86).
Regions are indicated as follows. Small t-ag common: region of large T-ag encoded in the first exon. The amino acid sequence in this region is
common to both large T-ag and small t-ag. Pola binding: regions required for binding to polymerase a-primase (103, 104, and references cited
therein). HSC70 binding: region required for binding the heat shock protein hsc70 (75). pRB/p107/p130 binding: region required for binding of the
RB tumor suppressor protein and the RB-related proteins p107 and p130 (104–106 and references cited therein). Nuclear localization: contains the
nuclear localization signal (107 and references cited therein). DNA binding: minimal region required for binding to SV40 ori DNA (24). Helicase:
region required for full helicase activity (108). Zn finger: region which binds zinc ions (104, 109, and references cited therein). p53 binding: regions
required for binding the p53 tumor suppressor protein (104, 110–112). ATP binding/ATPase: region containing the ATP binding site and ATPase
catalytic activity (104, 113, 114). Host range: region defined as containing the host range and Ad helper functions (92, 94, 96, 104, and references
cited therein). The circles containing a P indicate sites of phosphorylation found on large T-ag expressed in mammalian cells. S indicates a serine
and T indicates a threonine residue (104, 115, 116, and references cited therein).
SV40 was discovered in 1960 as a contaminant of plexus carcinoma (SVCPC) differed from the reference
strain, SV40-776, in several ways. First, the human iso-some viral vaccines prepared using monkey kidney cul-
tures (43, 44). Many people were inadvertently inoculated lates exhibited an archetypal regulatory region (con-
taining a single 72-base-pair enhancer element), a fea-with SV40 when they received contaminated poliovac-
cine in the late 1950s and early 1960s (45, 46). However, ture also noted in several fresh isolates of SV40 from
monkeys (59). Second, there was an A in place of a Cserologic surveys have indicated that populations with
very low risk of exposure to contaminated poliovaccine at nucleotide 2384 (based on the SV40-776 numbering)
in the VP1 coding region of most of the regions se-may have antibodies to SV40 (47–49), suggesting that
the virus may be present in the general population and quenced. This nucleotide change did not change the
predicted amino acid sequence. Third, they containedmaintained by some unknown transmission route. There
have been sporadic reports of the detection of SV40 DNA several differences in nucleotide sequence at the C-ter-
minus of the large T-ag gene which would result inor proteins in human tumors (45, 46, 50–53), although
there have also been reports of lack of detection of SV40 changes in the amino acid sequence of the oncoprotein.
In these previous studies (58, 59), only the C-terminusin human samples (54, 55, reviewed in 56). Recently,
SV40 early region DNA sequences were found to be of the large T-ag gene was sequenced. The variability
observed in the large T-ag C-terminal sequences of viralassociated with certain rare pediatric brain tumors of
humans (56) and with mesotheliomas (57). It was subse- isolates suggested that the large T-ag sequence may
be more variable than had been generally considered.quently shown that authentic SV40 was present in the
brain tumor samples, and infectious SV40 was isolated Therefore, we undertook a sequence comparison of the
early region of several isolates of SV40 obtained fromfrom one choroid plexus carcinoma (58).
The association of SV40 with human disease raised monkeys and humans and recovered over a span of 35
years. We report here the sequence of the entire large T-the possibility that subtle strain differences might exist
among viral isolates that have heretofore gone unde- ag and small t-ag coding regions of three human isolates:
SVPML-1 from a case of progressive multifocal leu-tected. Modern DNA sequence technology allowed us to
investigate this hypothesis. Our recent data also sup- koencephalopathy (60, 61), SVMEN from a meningioma
(62), and SVCPC from a choroid plexus carcinoma (58).ported the premise of potential SV40 genetic variation
(58). The SV40 sequences detected in the human brain Although SV40-776 is considered to be the reference
strain of the virus, other laboratory strains have beentumors and in the viral isolate recovered from a choroid
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FIG. 2. Differences in nucleotide (nt) coding strand sequence between SV40-776, SV40-B2, SVCPC, SVMEN, SVPML-1, and VA45-54. The sequence
of SV40-776 and the nucleotide numbering system are from Tooze (86). The shaded area indicates changes that fall in the unique region of small
t-ag. The genomes of SV40-B2, SVCPC, SVMEN, and SVPML-1 between nt 2691 and 5194 and the C-terminus of VA45-54 large T-ag were
sequenced using the Sequenase 2.0 sequencing kit (United States Biochemical/Amersham Life Sciences, Cleveland, OH) following the manufacturer’s
instructions. The remainder of the sequence of VA45-54 was contributed by M. J. Tevethia. The source of DNA for each strain was a full-length
viral genome cloned into either pBR322 or pUC19 (58, 60, 62, 71; M. J. Tevethia, unpublished). Sequences were analyzed using the GCG Sequence
Analysis Software Package (Genetics Computer Group, 1994, Program Manual for the Wisconsin Package, Version 8, Madison, WI) and the facilities
of the Molecular Biology Computational Resource, Information Technology Program and the Department of Cell Biology, Baylor College of Medicine.
Lack of a nucleotide in a column indicates identity with SV40-776. Nucleotides in boldface type indicate that the nucleotide change causes a change
in the amino acid sequence of the corresponding protein. dl indicates a deletion; ins indicates an insertion. The sequence inserted after nt 2795
is CAGCCCTCA in all instances where this insertion was detected. The sequence inserted after nt 2782 is CCTCACAGT.
widely used, usually with very little direct comparison one strain differs from SV40-776, the nucleotide is always
the same (e.g., see nucleotide position 4839 and 3117).among the various WT strains. Therefore, we have in-
cluded two other commonly used strains in our sequence This suggests that SV40-776 is not always representative
of strains found in nature or of other laboratory strains.analysis: SV40-B2 and VA45-54. SV40-B2, the Baylor
strain, was isolated from a type 2 polio vaccine prepara- Some of the observed nucleotide differences cause
the predicted amino acid sequence to also differ fromtion (63). It has been used in a range of structural and
functional studies, including tumor induction (64), trans- that of SV40-776 (Fig. 3). Amazingly, although nucleotide
differences were detected throughout the expanse of theformation of rodent and human cells (65, 66), tumor-spe-
cific transplantation antigen (TSTA) expression (67), p53 early region of the SV40 genome, the only amino acid
differences in the large T-ag protein would occur at theassociation (68), glycosylation (69), localization of large
T-ag to the plasma membrane (70–72), nuclear localiza- C-terminus. Some of these C-terminal differences were
described previously (58). The VA45-54 strain differs fromtion signal (71, 73), and interaction with hsc70 (74, 75).
VA45-54 was among the original isolates of SV40, as was SV40-776 at amino acids 623 and 634, has an insertion
at amino acid 674, and has a deletion of amino acids 683the reference strain SV40-776, although VA45-54 was
isolated from uninoculated grivet monkey kidney cul- and 684 (Fig. 3A). There were also amino acid changes
predicted for the small t-ag (Fig. 3B). All of the isolatestures, whereas SV40-776 was isolated from a contami-
nated adenovirus type 1 seed stock (44, 76). VA45-54 examined had a predicted substitution of Ile for Met at
amino acid 95 and Thr for Ala at amino acid 109. VA45-was selected because it was the parent for the derivation
of a series of temperature-sensitive mutants by Tegt- 54 had an additional difference at residue 104, where
Val was predicted in place of Ala.meyer and colleagues (77, 78) and by Tevethia and Rip-
per (79). These mutants have been extensively character- The conservation of the large T-ag sequence is im-
pressive. Except for the short variable region at the C-ized for their ability to immortalize and transform cells
(65, 80–83), to express CTL epitopes (84), and to induce terminus, the amino acid sequence of large T-ag was
absolutely conserved in viruses isolated from differentTSTA (67, 85).
The sequence of the entire early region, nucleotides species (SVPML-1, SVMEN, and SVCPC from humans;
SV40-B2 and VA45-54 from monkeys) and over a period2691–5194, was determined for each of the five SV40
isolates. The coding regions for both large T-ag and small of more than 30 years (SV40-776 and VA45-54 in 1960,
SV40-B2 in 1961, SVPML-1 in 1972, cloned in 1989,t-ag are included in this region. The numbering system
for the reference strain SV40-776 is used (86). All of the SVMEN in 1984, and SVCPC in 1995). Changes in the
p53, pRB, or DNA a-polymerase binding regions of largestrains sequenced display a number of differences when
compared with the nucleotide sequence of SV40-776 T-ag might theoretically alter the way in which large
T-ag interacts with these proteins in human cells, thereby(Fig. 2). It is noteworthy that at sites where more than
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giving the human isolates a growth advantage or in- region. It will be interesting to determine if the natural
isolates with differences in their large T-ag C-termini dis-creased tumorigenic potential in humans. However, no
amino acid changes were observed in those regions in play altered phenotypes in host-range assays and pos-
sess the Ad helper function.any of the viruses sequenced. Such conservation empha-
sizes the possible significance of the divergence present In addition, the C-terminus of large T-ag contains two
epitopes (amino acids 660–679 and 690–708) involvedat the C-terminus of large T-ag between amino acids 623
and 708 (Fig. 3A). Similar divergence at the C-terminus in the antibody response of BALB/c mice to large T-ag.
The epitope at the very C-terminus of large T-ag alsoof large T-ag was detected in a number of fresh SV40
isolates from macaques (59). contributed partial immunity to a tumorigenic challenge.
Neither peptide appeared to contribute to the antibodyThe C-terminal region of large T-ag contains a func-
tional domain, which encompasses amino acids 682 to or antitumor response of C57Bl/6 mice (99). These results
suggest the possibility that variations in the C-terminus708, defined as the host range/adenovirus (Ad) helper
domain (Fig. 1). The host range and Ad helper activities of large T-ag may play an important role in modulating
the ability of individual hosts to respond to both infectionare probably identical (87). Adenoviruses grow about
1000-fold less efficiently in monkey cells than in human and tumor formation by SV40.
The role of the SV40 small t-ag in viral replication andcells, but grow well in monkey cells coinfected with SV40
(88). A C-terminal fragment of SV40 large T-ag can relieve transformation processes has not been well-defined.
Two roles so far ascribed to small t-ag are inhibitionthe Ad replication block in monkey cells (88–91) by an
unknown mechanism. The host-range function was iden- of PP2A and stabilization of p53. Two different regions
identified as being important for PP2A binding are be-tified when it was observed that large T-ag C-terminal
deletion mutants exhibited different growth properties in tween amino acids 97 and 103 (100) and from 111 to 131
(32). Neither of those regions includes a variable aminostable monkey cell lines; whereas the deletion mutants
of SV40 grew very poorly in CV-1 cells, they grew almost acid reported here. Studies of small t-ag/PP2A interaction
were conducted using strain WT830. The small t-ag cod-as well as WT virus in BSC40 cells (92–94) and in BSC-
1 and Vero cells (95), although that growth was tempera- ing region of WT830 has been sequenced (101) and is
identical to that of VA45-54 (Fig. 3B). Both SV40-776 andture-sensitive (92, 95). Viral DNA was replicated to near
WT levels in all three cell types and at the nonpermissive WT830 were capable of cell transformation in an assay
dependent on the small t-ag/PP2A interaction (102; K.temperature in BSC-1, BSC40 and Vero cells (18, 92, 96),
but viral mRNA levels were reduced and the mRNAs did Rundell, personal communication), suggesting that the
differences observed in the small t-ag sequence betweennot utilize the same start sites as in WT infections. The
quantity of viral structural proteins was reduced in cells the two viral strains do not affect the interaction with
PP2A. The study of small t-ag effects on stabilization ofinfected with the mutants, and the agnoprotein was not
detected at all (96); however, providing the agnoprotein p53 also utilized WT830 (33). It remains to be determined
whether strains which encode a small t-ag with somein trans did not restore WT production of virus (87). Re-
cently, it has been shown that virions produced by the amino acid differences can also contribute to p53 stabili-
zation. Although small t-ag expression affects the spec-large T-ag C-terminal mutants do not assemble properly
and that this failure is probably due to an inability to add trum of tumors observed in transgenic mice and in ham-
sters injected with SV40 (34, 35), the activities of smallVP1 to the 75S assembly intermediates (97). Precisely
how the C-terminus of large T-ag affects the addition of t-ag contributing to this effect have not been explored. It
will be important to determine if the variability in smallVP1 during virion assembly and how this requirement is
bypassed in BSC-1, BSC40, and Vero cells has not been t-ag sequence reported here affects the tumorigenic po-
tential of different SV40 strains.determined. Phosphorylation on C-terminal Ser and Thr
residues does not appear to be involved because these In summary, both the large and small tumor antigen
coding regions of SV40 natural isolates and laboratoryresidues can be mutated without altering either host-
range or Ad helper functions (97, 98). strains contain sequence differences when compared
with reference strain SV40-776. Large T-ag showed sig-The studies of host-range function have been carried
out with mutants derived from SV40-776 or WT830 (for- nificant variation in amino acid sequence in the C-termi-
nal region, which we have termed the variable domain.merly called SV-S). The Ad helper function studies have
been performed with SV40 strain WT830 (89) and SV40- This interpretation is supported by recent analysis of the
C-terminal sequences of large T-ag from several natural777 (88) and with Ad2-SV40 hybrid viruses (90, 91). To
our knowledge, the sequences of WT830 and SV40-777 SV40 isolates of monkeys, which also showed significant
variation when compared to the SV40-776 referencelarge T-ag coding region have not been reported. There-
fore, the large T-ag characterized to date for Ad helper strain (59). The remainder of the large T-ag amino acid
sequences studied here were found to be absolutelyand host-range functions are either 776 or of unknown
sequence. Some of the C-terminal differences noted in conserved. This analysis emphasizes the constraints
placed on a highly multifunctional protein, such as largenatural isolates (58, 59) fall in the Ad helper/host-range
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25. Lewis, A. M., Jr., and Martin, R. G., Proc. Natl. Acad. Sci. USA 76,T-ag, whereby apparently little or no flexibility is allowed
4299–4302 (1979).in sequence alteration without disrupting an essential
26. Bikel, I., Montano, X., Agha, M. E., Brown, M., McCormack, M.,
biological function. It also focuses attention on the C- Boltax, J., and Livingston, D. M., Cell 48, 321–330 (1987).
terminal domain of large T-ag, as the variation found 27. Cicala, C., Pompetti, F., Nguyen, P., Dixon, K., Levine, A. S., and
Carbone, M., Virology 190, 475–479 (1992).there suggests possible selection of functional variants
28. de Ronde, A., Sol, C. J. A., van Strien, A., ter Schegget, J., and vanunder different conditions in natural infections in intact
der Noordaa, J., Virology 171, 260–263 (1989).hosts. The small t-ag sequences displayed several amino
29. Pallas, D. C., Shahrik, L. K., Martin, B. L., Jaspers, S., Miller, T. B.,
acid substitutions in the unique region compared to the Brautigan, D. L., and Roberts, T. M., Cell 60, 167–176 (1990).
reference strain. It should be noted that both the large 30. Yang, Y.-C., Hearing, P., and Rundell, K., J. Virol. 32, 147–154
(1979).and small tumor antigen sequences of the studied iso-
31. Yang, S.-I., Lickteig, R. L., Estes, R., Rundell, K., Walter, G., andlates were more similar to each other than to SV40-776.
Mumby, M. C., Mol. Cell. Biol. 11, 1988–1995 (1991).This suggests that the sequences of the SV40-776 tumor
32. Sontag, E., Fedorov, S., Kamibayashi, C., Robbins, D., Cobb, M.,
antigens are not the best representatives of what exists and Mumby, M., Cell 75, 887–897 (1993).
in nature. This variability should be considered when 33. Tiemann, F., Zerrahn, J., and Deppert, W., J. Virol. 69, 6115–6121
(1995).comparing results of experiments performed using differ-
34. Choi, Y., Lee, I., and Ross, S. R., Mol. Cell. Biol. 8, 3382–3390ent strains of SV40.
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35. Matthews, B.-J., Levine, A. S., and Dixon, K., J. Virol. 61, 1282–
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